Back to results
US 11,299,547 B2Granted
CMET monoclonal binding agents, drug conjugates thereof and uses thereof
AssigneeMitsubishi Tanabe Pharma Corporation
InventorsJulia Coronella, Vincent Blot, Marco Gymnopoulos, Anjuli Timmer, Ryo Fujita, Roland Newman
Life of this patent
Estimating the term…
Abstract
Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.
Claims20
A binding agent comprising:
- a CDR-L1 selected from SEQ ID NOs:
- 1-15,
- a CDR-L2 selected from SEQ ID NOs:
- 16-25,
- a CDR-L3 selected from SEQ ID NOs:
- 26-36,
- a CDR-H1 selected from SEQ ID NOs:
- 50-61,
- a CDR-H2 selected from SEQ ID NOs:
- 62-78, and
- a CDR-H3 selected from SEQ ID NOs:
- 79-93
- wherein the binding agent specifically binds to an extracellular domain of mesenchymal epithelial transition factor (cMET).
10 more elements
Dependencies are inferred from the claim text.